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Summary Patients with chronic liver disease (CLD) often develops glucose intolerance. We
explored the prevalence of diabetes mellitus in viral CLD, and analyzed factors profoundly
affecting the diabetic angiopathies. 229 CLD patients (124 chronic hepatitis and 105 liver
cirrhosis) entered the study. The diagnosis of diabetes was made with the criteria by World
Health Organization. Laboratory investigation included serum asparate aminotransferase,
alanine aminotransferase, albumin, fasting blood sugar, hemoglobin A1c (HbA1c), fasting
immunoreactive insulin, and HOMA-R (FBS*IRI/405). The incidence of macro- and micro-
angiopathy were also examined. Forty (17.5%) CLD patients were diagnosed diabetes, giving
a significantly higher incidence than that of general cohort (5.3%) (p<0.001). Among them, 12
(30%) had the triopathy, significantly lower than that in a matched group of diabetic patients
without CLD (65%) (p<0.001). Significantly increased levels of HbA1c and HOMA-R were
observed in diabetic CLD with angiopathy compared with diabetic CLD without. Incidence of
diabetes was increased in viral CLD patients. The rate of diabetic angiopathies in CLD,
however, was relatively low, this could be explained by low coagulability in these patients.
Poor control of hyperglycemia, partly due to insulin resistance, might explain the onset of
angiopathy in diabetic CLD.
Key Words: hepatogenous diabetes, chronic liver disease, diabetes mellitus, insulin resistance,
glucose intolerance
Introduction
Patients with chronic liver disease (CLD) are characterized
by impaired glucose tolerance [1–4]. In particular, 50–80%
of cirrhotic patients are glucose intolerant, and 10–20% of
them develop diabetes mellitus (DM) [2,  5–11]. Insulin
resistance has been suggested as the major cause of such
glucose intolerance in cirrhotic patients [12, 13]. The impact
of hepatogenous DM [1, 3] has been recently reported to
worsen long-term prognosis caused by hepatic failure [3,
6, 14]. Diabetic macroangiopathy (cardiac events, stroke,
and peripheral arterial disease) as well as microangiopathy
(retinopathy, neuropathy, and nephropathy) in cirrhotics
were, however, relatively rare as compared to those in DM
alone [14].
Reported studies as to the occurrence of diabetes in liver
disease, however, employed mostly the alcoholic CLD [3, 5,
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15–18]. Alcohol damages the pancreas directly, leading to
insufficient secretion of insulin. The association of hepatitis
C virus infection with the development of DM has been also
suggested [5, 7–9, 19]. However, incidence and significance
of diabetic angiopathies in chronic viral liver disease have
not yet been clarified.
We here conducted a study to elucidate the prevalence of
DM and the incidence of diabetic macro- and microangiopathy
in chronic viral liver disease, and to characterize the clinical
background of those patients.
Materials and Methods
Patients
The subjects consisted of 229 patients with CLD aged
61 years (median, range 24–87 years) who were either
hospitalized or followed-up at the outpatient clinic between
January 2000 and March 2001. Of those patients, 124 (90
males and 34 females) were diagnosed as chronic hepatitis,
and 105 (69 males and 36 females) were liver cirrhosis.
The etiologies of liver disease were hepatitis B virus in 51
patients and hepatitis C in 178 patients. Clinical characteristics
of the patients are given in Table 1.
Three hundred and forty five non-insulin dependent DM
patients without CLD from our hospital were also included
in this study as a disease-control group against diabetic CLD
patients. Informed consent was obtained from each subject.
Methods
Diagnosis of chronic hepatitis or liver cirrhosis was based
on liver biopsy, blood examination, and imagings such as
ultrasound or computed tomography. The demographic data
including age, sex, alcohol drinking, duration of liver disease,
duration of diabetes, and family history of diabetes were
collected. Body mass index (BMI) was calculated as body
weight in kilograms divided by the square of height in
meters (kg/m2). Patients with autoimmune hepatitis, alcoholic
hepatitis, Wilson’s disease, hemochromatosis, drug-induced
hepatitis, or hepatitis of unknown cause were excluded from
the study.
Serum total bilirubin (T-Bil), aspartate aminotransferase
(AST), alanine aminotransferase (ALT), albumin (Alb), fasting
blood sugar (FBS), platelet count (Plt), triglyceride (TG),
total cholesterol (T-cho), and urine protein were measured
by standard methods. Severity of liver cirrhosis was graded
by Child-Pugh classification [20]. Diabetes was diagnosed
according to the current World Health Organization (WHO)
criteria [21]. Mild glucose intolerance was not included in
the diagnosis of diabetes. The presence of hypertension, or
the development of hepatocellular carcinoma (HCC) was
also recorded.
For CLD patients with diabetes, glycosylated hemoglobin
(HbA1c) and fasting immunoreactive insulin (IRI) were
measured. The insulin resistance was calculated on the basis
of fasting plasma levels of glucose and insulin according to
the HOMA model as follows [22]:
Insulin resistance (HOMA-R)=fasting insulin (µU/ml)×
Table 1. Clinical characteristics of the 229 patients with chronic liver damage
Characteristic Chronic hepatitis Liver cirrhosis p value*
No. of patients 124 105
Age (years) 57 (24–78) 64 (32–87) p<0.001
Gender (male/female) 90/34 69/36 ns
Etiology (HBV/HCV) 30/94 21/84 ns
No. with HCC 7 (6%) 49 (47%) p<0.001
No. with Hypertension 15 (12%) 21 (20%) ns
BMI (kg/m2) 22.4 (16.7–32.4) 22.3 (14.5–32.2) ns
T-Bil (mg/dl) 0.8 (0.4–1.1) 1.2 (0.4–2.6) p<0.05
AST (IU/l) 49 (15–186) 68 (14–346) p<0.001
ALT (IU/l) 57 (7–274) 56 (9–195) ns
FBS (mg/dl) 102 (72–225) 92 (69–124) p<0.01
Alb (g/dl) 4.1 (2.6–4.8) 3.6 (2.3–4.7) p<0.001
PT (%) 84 (55–100) 70 (41–100) ns
Plt (×104/µl) 17.0 (5.0–34.2) 11.8 (2.4–33.2) p<0.001
Values are expressed as median (range). *by Mann-Whitney’s U test or Fischer’s exact
probability test. Abbreviations used are; HBV, hepatitis B virus; HCV, hepatitis C virus; BMI,
body mass index; HCC, hepatocellular carcinoma; T-Bil, total bilirubin; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; FBS, fasting blood sugar; Alb, serum
albumin; PT, prothrombin time; Plt, platelet count; ns, not significant.S. Kuriyama et al.
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fasting glucose (mg/dl)/405
In order to determine the presence of triopathy, the patients
were further examined by ophthalmologists for retinopathic
complications, and by the measurement of urinary trace
albumin, blood urea nitrogen (BUN) and creatinine (Cr) for
nephropathy. Neurological examinations on patellar tendon
reflex and Achilles tendon reflex, and on paralysis of the feet
were carried out for neuropathy. The CLD patients with
diabetes were categorized into two groups: those with either
of thriopathy and those without triopathy.
The study protocol conformed to the ethical guideline of the
1975 Declaration of Helsinki as reflected in a prior approval
by the institution’s review board for human research [23].
Statistical analysis
The results are expressed as median and range. For statis-
tical comparison between median values, Mann-Whitney’s
U test was used. Fisher’s exact test was used to compare
incidences. All statistical tests performed were two-tailed.
Difference was considered significant when p value was less
than 0.05. All analyses were performed using Stat View 5.0
for Macintosh (SAS Institute, Cary, NC).
Results
Forty patients with chronic liver disease (11 chronic
hepatitis and 29 liver cirrhosis) were diagnosed diabetes
(Table 2). This incidence of diabetes in CLD (40/229, 17.5%)
was significantly higher than that in an age- and sex-matched
general cohort (5.3%) obtained from reference 1 (p<0.001
by chi-square test). The incidence of DM in LC (29/105,
27.6%) was significantly higher than that in CH (11/124,
8.9%) (p<0.001) (Table 2). In CH, all patients with DM were
HCV-positive while no HBV(+)-CH patient presented DM
(p<0.05, Table 2). In contrast, such difference between HCV
and HBV was not found in LC. There was no significant
difference in clinical parameters, except FBS and HbA1c,
between CLD patients with DM and those without DM.
Among 40 CLD patients with DM, 12 (30%) were com-
plicated with diabetic triopathy (Table 3). This incidence in
diabetic CLD was significantly lower than that in DM
without CLD (225/345, 65%) (p<0.001). Such difference
was due to a significantly lower incidence of retinopathy in
diabetics with CLD (p<0.05). The incidence of neuropathy
in diabetics with CLD tended to be also lower than those
without CLD (p=0.06), while the incidence of nephropathy
was not different between both groups (Table 3). Only one
patient (1/40, 2.5%) developed a major cardio-vascular
event and cerebral infarction that is considered to result from
hepatogenous diabetes.
Clinical characteristics of 40 diabetic CLD patients were
compared with those of 345 diabetic patients without liver
disease (Table 3). There was no significant difference in
age, gender, BMI, and treatment modalities between the
Table 2. Incidence of diabetes mellitus in chronic liver damage
Characteristic DM(−)D M ( + ) p value*
No. of patients 189 (82.5%) 40 (17.5%)
Age 64 (24–87) 65 (53–77) ns
Gender (male/female) 132/57 27/13 ns
CH/LC 113/76 11/29 p<0.001
CH (HBV/HCV) 30/83 0/11 p<0.05




BMI (kg/m2) 22.0 (14.5–32.2) 22.3 (16.9–32.4) ns
No. with HCC 51 (27%) 13 (33%) ns
AST (IU/l) 68 (15–346) 62 (21–154) ns
ALT (IU/l) 56 (7–274) 51 (9–166) ns
FBS (mg/dl) 92 (72–125) 148 (69–225) p<0.01
HbA1c (%) 4.8 (3.5–6.3) 6.8 (4.3–10.8) p<0.01
Alb (g/dl) 3.6 (2.3–4.8) 3.5 (2.3–4.7) ns
Plt (×104/µl) 11.8 (2.5–34.2) 9.9 (2.4–28.6) ns
Values are expressed as median (range). *by Mann-Whitney’s U test or chi-square test.
Abbreviations used are; DM, diabetes mellitus; CH, chronic hepatitis; LC, liver cirrhosis;
HBV, hepatitis B virus; HCV, hepatitis C virus; BMI, body mass index; HCC, hepatocellular
carcinoma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FBS, fasting
blood sugar; HbA1c, glycosylated hemoglobin; Alb, serum albumin; Plt, platelet count; ns,
not significant.Diabetes and Angiopathy in CLD
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two groups. While blood biochemical parameters such as
FBS, HbA1c, HOMA-R, and IRI were similar, Plt, blood
coagulation activity indicated by prothrombin time (PT), TG,
and T-cho were significantly lower in diabetic CLD than in
DM without CLD (Table 3).
Clinical characteristics of diabetic CLD patients with and
without triopathy are shown in Table 4. Those with triopathy
had a significantly longer morbidity period of diabetes
(p<0.05) and received insulin injection at a higher rate
(p<0.05) than diabetic CLD without triopathy.
Blood biochemical data in diabetic CLD patients with and
without triopathy are given in Table 5. Significant difference
was observed in HbA1c and HOMA-R between the two
groups, suggesting hyperglycemia for a longer period and
insulin resistance in the former group. No difference in liver
function tests was observed between two groups.
Discussion
The incidence of diabetes as a complication of chronic
liver disease is reported to be 13% in chronic alcoholic
hepatitis and 14 to 63% in alcoholic liver cirrhosis [5, 9, 15–
17]. However, there have been few reports as to the
incidence of diabetes in viral liver disease [16].
Zein reported 25% of cirrhotic patients before trans-
plantation had diabetes [16]. In our study, 8.9% of patients
with chronic viral hepatitis and 27.6% of patients with
viral liver cirrhosis were complicated with diabetes. Thus,
significantly higher incidence of diabetes was observed in
chronic liver disease.
There were a few differences between diabetic patients
with liver disease (diabetic CLD) and authentic diabetic
patients. The most pronounced was that, very few patients
had a family history of diabetes in diabetic CLD (4/40,
10%), whereas more than 50% of the latter patients showed
that. This is because diabetic state in CLD could be acquired
secondary to liver disease per se, not due to genetic back-
ground as in most non-insulin dependent diabetes mellitus
(NIDDM).
The pathogenesis of diabetes in liver disease is not fully
understood. In alcoholic liver disease, reduced insulin secre-
tion due to pancreatic damage could be the cause of impaired
glucose metabolism. However, that may not be the case of
diabetes in viral liver disease, because excess insulin secre-
tion is observed after glucose loading in liver cirrhosis [24].
Glucose uptake into hepatocytes after glucose absorption is
delayed due to decreased hepatocyte mass in CLD, leading to
hyperinsulinemia. Subsequent continuous hyperinsulinemic
Table 3. Clinical characteristics of diabetic CLD patients and diabetic patients without CLD
DM without CLD Diabetic CLD p value*
No. of patients 345 40
Age (years) 60 (15–87) 65 (53–77) ns
Gender (male/female) 155/190 27/13 ns
BMI (kg/m2) 22.8 (16.2–31.8) 23.2 (16.9–32.4) ns
FBS (mg/dl) 120 (41–303) 148 (69–225) ns
HbA1c (%) 6.7 (4.2–12.0) 6.8 (4.3–10.8) ns
HOMA-R 8.3 (0.72–17.58) 6.9 (0.88–32.2) ns
Insulin 28 (3.1–63.0) 26 (4.4–110) ns
TG (mg/dl) 128 (33–430) 82 (33–233) p<0.05
T-cho (mg/dl) 195 (127–387) 141 (70–221) p<0.001
PT (%) 89 (77–96) 72 (40–100) p<0.001
Plt (×104/µl) 23.8 (12.8–33.4) 9.9 (2.4–28.6) p<0.001
Treatment
Diet 49 (14%) 10 (25%)
Drug 128 (37%) 17 (43%) ns
Insulin 168 (49%) 13 (32%)
Triopathy 225 (65%) 12 (30%) p<0.001
Retinopathy 133 (39%) 8 (20%) p<0.05
Neuropathy 121 (35%) 8 (20%) p=0.06
Nephropathy 57 (17%) 4 (10%) ns
Values are expressed as median (range). *by Mann-Whitney’s U test or chi-square test. Abbreviations
used are; DM, diabetes mellitus; CLD, chronic liver disease; BMI, body mass index; FBS, fasting blood
sugar; HbA1c, glycosylated hemoglobin; HOMA-R, homeostasis model assessment; Alb, serum albumin;
TG, triglyceride; T-cho, total-cholesterol; PT, prothrombin time; Plt, platelet count; ns, not significant.S. Kuriyama et al.
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Table 4. Clinical characteristics of diabetic CLD patients with and without diabetic triopathy
Triopathy (−)( + ) p value*
No. of patients 28 12
Age (years) 64 (53–77) 66 (57–77) ns
Gender (male/female) 19/9 8/4 ns
Etiology HBV/HCV 3/25 2/10 ns
CH/LC 7/21 4/8 ns
CH HBV/HCV 0/7 0/4 ns
LC HBV/HCV 3/18 2/6 ns
Child-Pugh classification A/B/C 11/6/4 5/3/0
BMI (kg/m2) 23.4 (16.9–32.4) 23.1 (19.4–27.0) ns
Duration of liver disase (years) 9 (2–19) 10 (4–19) ns
Duration of DM (years) 5 (1–14) 8 (1–16) p<0.05
Treatment Diet 10 (36%) 0 (0%) p<0.05
Drug 11 (39%) 6 (50%)
Insulin 7 (25%) 6 (50%)
Hypertension 7 (25%) 4 (33%) ns
HCC 10 (36%) 4 (33%) ns
Family history of DM 1 (3.6%) 3 (25%) p<0.05
Values are expressed as median (range). *by Mann-Whitney’s U test or chi-square test. Abbreviations used are;
CLD, chronic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; CH, chronic hepatitis; LC, liver
cirrhosis; BMI, body mass index; DM, diabetes mellitus; HCC, hepatocellular carcinoma; ns, not significant.
Table 5. Biochemical analysis of diabetic CLD patients with and without diabetic
triopathy
Triopathy (−)( + ) p value*
No. of patients 28 12
FBS (mg/dl) 127 (69–257) 172 (110–266) p<0.001
HbA1c (%) 6.3 (4.3–9.2) 7.6 (5.7–10.8) p<0.05
Insulin (U/ml) 22 (4.5–33.0) 34 (9.3–69.1) ns
HOMA-R 4.1 (0.88–9.49) 13.5 (3.1–32.2) p<0.05
TG (mg/dl) 84 (33–205) 80 (39–233) ns
T-cho 135 (70–221) 151 (94–216) ns
T-Bil (mg/dl) 1.4 (0.4–4.9) 1.0 (0.7–1.4) ns
AST (IU/l) 63 (21–154) 51 (24–97) ns
ALT (IU/l) 54 (9–166) 47 (17–83) ns
Alb (g/dl) 3.5 (1.8–4.7) 3.4 (2.4–4.3) ns
PT (%) 72 (51–99) 81 (58–100) ns
Plt (×104/µl) 9.7 (2.4–28.6) 10.1 (3.9–18.8) ns
CH 12.8 (10.1–28.6) 16 (8.1–18.8) ns
LC 7.1 (2.4–15) 7.6 (3.9–14.6) ns
Values are expressed as median (range). *by Mann-Whitney’s U test or chi-square
test. Abbreviations used are; CLD, chronic liver disease; FBS, fasting blood sugar;
HbA1c, glycosylated hemoglobin; HOMA-R, homeostasis model assessment; TG,
triglyceride; T-cho, total-cholesterol; T-Bil, total bilirubin; AST, aspartate amino-
transferase; ALT, alanine aminotransferase; Alb, serum albumin; PT, prothrombin
time; Plt, platelet count; CH, chronic hepatitis; LC, liver cirrhosis; ns, not significant.Diabetes and Angiopathy in CLD
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state could eventually induce insulin resistance in the
patients. Previous reports suggested that insulin resistance,
characterized by both decreased glucose transport and
decreased nonoxidative glucose metabolism in skeletal
muscle, could be the cause of diabetes in liver cirrhosis
[25]. In addition, glucose effectiveness, glucose metabolic
pathway independent of insulin secretion, is also reduced in
cirrhotic patients [4, 26].
A strong association between HCV infection and diabetes
has been recently suggested. Mason reported that HCV
infection and age were independent predictors of diabetes, and
significantly higher prevalence of HCV infection, especially
genotype 2a, was observed in diabetic patients as compared
to non-diabetic hepatitis C patients [8]. Recognized diabetic
factors such as age or obesity may increase the risk for type
2 diabetes in HCV-infected persons [27]. We have found
higher incidence of DM in chronic hepatitis C than in
chronic hepatitis B (Table 2), and also obesity tendency in
chronic hepatitis C with DM compared to CH(C) without
DM (BMI 25 ± 4 : 22 ± 3 kg/m2, p=0.08). Additionary higher
prevalence of diabetes was observed in liver cirrhosis as
compared to that in chronic hepatitis. Furthermore, in contrast
to CH, no difference was found in the incidence of DM
between HBV-positive cirrhotics and HCV-positive ones.
These observations suggest that severity of liver disease
could increase by itself the risk of diabetes in CLD.
We showed significantly lower incidence of macro- and
microangiopathy in patients with diabetic CLD than in
authentic diabetic patients (Table 3), in a similar manner
to ref [28]. As for macroangiopathy, there was only one
patient (2.5%) with cerebral infarction who developed
cardio-vascular event possibly attributable to diabetes in
CLD group. Microangiopathy was observed in 12 patients
(30%). Progressive retinopathy was observed in two patients
who had a history of diabetes lasting 10 years and 8 years,
respectively. There were two patients (5%) with diabetic
neuropathy, who were on medication such as Epalrestat
(Kinedak®). Positive trace albumin in urine, ophthalmologic
abnormality, and neurological impairment were identified
in other eight patients without any subjective symptom.
Although the incidence of triopathy in diabetic CLD was
significantly lower, the proportion of retinopathy, neuropathy,
and nephropathy did not differ between diabetic CLD
(2:2:1) and DM without CLD (2.3:2.1:1) (Table 3). Thus, the
detection (or non-detection) of statistical significance for the
difference in the incidence of each of triopathy between 2
groups (Table 3) may have depended solely on the size of the
number of each event.
This study clarified that several factors might affect the
occurrence of diabetic macro- and microangiopathy in CLD.
First, significantly longer duration and frequent family history
of diabetes were observed in CLD patients with diabetic
triopathy as compared to those without triopathy. Poor
control of blood glucose level, indicated by high FBS
and HbA1c, could also be a cause of diabetic triopathy.
Interestingly, significantly higher level of HOMA-R was
also observed in the group with diabetic triopathy,
suggesting insulin resistance might have an impact as a
factor for diabetic triopathy. Therefore, improvement of
insulin resistance would be important to prevent diabetic
angiopathy also in liver disease. Further prospective study is
needed to find the relevance between diabetic angiopathy
and insulin resistance in CLD patients.
Significant decreases in platelet count and PT were
observed in CLD with diabetes as compared with authentic
diabetic patients as shown in Table 3. It has been reported that
increased platelet aggregation is associated with the develop-
ment of diabetic complications, and strict blood sugar control
could improve platelet aggregation and prevent thriopathy
[29]. Decreased production of coagulation factors from the
liver might also help preventing intravascular coagulation
promoted by hyperglycemia in diabetic state [30,  31],
leading to a low rate of angiopathy in diabetic CLD patients.
It is difficult to avoid some limitations in this kind of
clinical study. The limitation in this study is the lack of area
under the curve (AUC) analysis of oral glucose tolerance
test (OGTT), since AUC better estimates the grade of
glucose intolerance in LC than HbA1c. This study was a
retrospective cross-sectional study, and we could obtain only
the diagnosis in the chart, but not the raw OGTT data to
calculate AUC.
In conclusion, high incidence of diabetes was observed in
viral CLD. Low intravascular coagulability may explain
relatively lower rate of diabetic complication in CLD. How-
ever, poor control of hyperglycemia, partly due to insulin
resistance, could contribute to the pathogenesis of angiop-
athy in diabetic CLD. Strict control of blood glucose and
improvement of insulin resistance, therefore, should be
directed in patients with diabetic CLD to help prevent
diabetic angiopathy in those patients.
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